Litronesib clinical trials
Also written LY2523355.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses litronesib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY2523355
- 7
Studies by the year they started
7 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses litronesib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of LY2523355 in Participants With Breast CancerCompletedPhase 2Eli Lilly and CompanyNCT01416389Written as LY2523355How we know
- A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2Eli Lilly and CompanyNCT01059643Written as LY2523355How we know
- A Study for Participants With Small-Cell Lung CancerCompletedPhase 2Eli Lilly and CompanyNCT01025284Written as LY2523355How we know
- A Study for Patients With Acute LeukemiaTerminatedPhase 1Eli Lilly and CompanyNCT01214655Written as LY2523355How we know
- A Study for Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01214629Written as LY2523355How we know
- A Dose-Escalation Study for Patients With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01214642Written as LY2523355How we know
- A Study of LY2523355 in Patients With Solid CancerCompletedPhase 1Kyowa Kirin Co., Ltd.NCT01358019Written as LY2523355How we know
Codes
What other systems call litronesib · ClinicalTrials.gg INT000074
- MeSH (NLM) C000591843litronesibOne source NLM
- UNII (FDA) 6611F8KYCVLITRONESIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27263928litronesibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88328LitronesibOne source FDA
- DrugBank DB11861One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000591843 | litronesib | One source NLM |
| UNII (FDA) | 6611F8KYCV | LITRONESIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27263928 | litronesib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88328 | Litronesib | One source FDA |
| DrugBank | DB11861 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.